Table I.
Study design and patient demographics
| Treatment | No. Papers | LOE | MINORS Score | N (M/F) | Age (y) | Follow-up (months) |
|---|---|---|---|---|---|---|
| Physical Therapy | 3 | III (1); IV (2) | 89.6% | 94 (59/35) | 68.3 (54–89) | 32 (24–65) |
| Debridement | 7 | III (1); IV (6) | 88.8% | 256 (160/96) | 65.7 (33–82) | 48 (24–120) |
| Partial Repair | 7 | III (1); IV (6) | 89.0% | 226 (122/93)* | 62.7 (33–81) | 45.2 (24–90) |
| Graft Interposition | 3 | IV (3) | 85.4% | 67 (39/28) | 68.2 (51–85) | 34.3 (24–86) |
| Tendon Transfer | 11 | III (1); IV (10) | 88.1% | 506 (319/187) | 59.2 (53–64.2) | 57.7 (24–147) |
| Arthroscopic-Assisted | 4 | IV (4) | 89.1% | 144 (68/76) | 61.7 (59–64.2) | 70.2 (24–147) |
| Open | 7 | III (1); IV (6) | 87.5% | 362 (251/111) | 57.7 (53–61) | 35.8 (24–77) |
| SCR | 4 | IV (4) | 81.3% | 179 (12/11)* | 64.7 (43–82) | 44.5 (24–60+) |
| HDA | 1 | IV | 87.5% | 38 | 59.4 | 24 |
| TFL | 3 | IV (3) | 79.2% | 141 (12/11)* | 66.4 (65.1–68.0) | 51.4 (24–110) |
| Balloon | 2 | IV (2) | 93.8% | 25 | 68.8 (54–85) | 42 (24–60) |
| RSA | 6 | IV (6) | 85.4% | 247 (48/74)* | 67.5 (34–86) | 39.4 (24–118) |
MINORS score represented as weighted average for each treatment strategy.
N=Total number of patients per treatment group reported; M=male; F=female.
Age and follow-up reported as mean (range) in years and months, respectively.
LOE Level of evidence
SCR Superior Capsular Reconstruction
RSA Reverse Shoulder Arthroplasty
AA Arthroscopic-Assisted
HDA Human Dermal Allograft
TFL Tensor Fascia Lata Autograft
*
Incomplete reporting of number of patients based on gender